Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City (ACCP)
The Company has announced that it will be presenting at a joint international symposium of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) on Supportive Care in Cancer, in which the results of a recent interim analysis of data from an ongoing MuGard clinical trial will be shared.
On Thursday June 28th, a podium presentation will be made by one of the lead investigators in the study, and on Friday June 29th results will be presented in a poster on display. In addition to these presentations, "Access will have its MuGard booth in the commercial exhibit hall to educate the attendees on the clinical benefit MuGard offers patients undergoing cancer treatment. The annual MASCC/ISOO Symposium is the preeminent international conference to focus on supportive care in oncology and will be held this week at the Hilton New York Hotel on Thursday, June 28th – Saturday, June 30th."